COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,386 Articles (22,816 medRxiv, 8,570 bioRxiv)

Most recent first Previous |  Page 984: Articles 9831-9840  | Next

Effect of SARS-CoV-2 spike mutations on its activation by TMPRSS2 and TMPRSS13
Stevaert, A., Van Berwaer, R., Raeymaekers, V., Laporte, M., Naesens, L. M. J.
10.1101/2022.01.26.477969 — Posted: 2022-01-27
Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19
Peddireddy, S. P., Rahman, S. A., Cillo, A. R., Vijay, G. M., Somasundaram, A., Workman, C. J., Bain, W., McVerry, B. J., Methe, B., Lee, J. S., Ray, P., Ray, A., Bruno, T. C., Vignali, D. A., Kitsios, G. D., Morris, A., Singh, H., Sarkar, A., Das, J.
10.1101/2022.01.24.477545 — Posted: 2022-01-27
Defining the Substrate Envelope of SARS-CoV-2 Main Protease to Predict and Avoid Drug Resistance
Shaqra, A. M., Zvornicanin, S., Huang, Q. Y., Lockbaum, G. J., Knapp, M., Tandeske, L., Barkan, D. T., Flynn, J., Bolon, D. N., Moquin, S., Dovala, D., Kurt Yilmaz, N., Schiffer, C. A.
10.1101/2022.01.25.477757 — Posted: 2022-01-27
Impact of various vaccine boosters on neutralization against Omicron following prime vaccinations with inactivated or adenovirus-vectored vaccine
Huang, Q., Zeng, J., Lang, Q., Gao, F., Liu, D., Tian, S., Shi, R., Luo, L., Wang, H., Hu, L., Jiang, L., Liu, Y., Li, K., Wu, Y., Xu, J., Jiang, W., Guo, N., Chen, Z., Hao, X., Jin, R., Yan, J., Sun, Y.
10.1101/2022.01.25.476850 — Posted: 2022-01-27
TNFα-producing CD4+ T cells dominate the SARS-CoV-2-specific T cell response in COVID-19 outpatients and are associated with durable antibodies
van der Ploeg, K., Kirosingh, A. S., Mori, D. A. M., Chakraborty, S., Hu, Z., Seivers, B. L., Jacobson, K. B., Bonilla, H., Parsonnet, J., Andrews, J. R., Press, K. D., Ty, M. C., Ruiz-Betancourt, D. R., de la Parte, L., Tan, G. S., Blish, C. A., Takahashi, S., Rodriguez-Barraquer, I., Greenhouse, B., Singh, U., Wang, T. T., Jagannathan, P.
10.1101/2022.01.25.22269670 — Posted: 2022-01-26
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Hager, K. J., Marc, G. P., Gobeil, P., Diaz, R. S., Heizer, G., Llapur, C., Makarkov, A. I., Vasconcellos, E., Pillet, S., Riera, F., Bhutada, K., Wolff, P. G., Wallace, G., Aazami, H., Jones, C. E., Polack, F. P., Atkins, J., Boulay, I., Dhaliwall, J., Charland, N., Couture, M., Jiang-Wright, J., Landry, N., Lapointe, S., Lorin, A., Mahmood, A., Moulton, L. H., Pahmer, E., Parent, J., Saxena, P., Seguin, A., Tran, L., Breuer, T., Ceregido, M. A., Koutsoukos, M., Roman, F., Namba, J., D'Aoust, M.-A., Trepanier, S., Kimura, Y., The CoVLP Study Team, , Ward, B. J.
10.1101/2022.01.17.22269242 — Posted: 2022-01-26
Comparative diagnostic performance of the new chromatographic Affimer(R)-based rapid antigen detection against SARS-CoV-2 and other standard antigen tests for COVID-19 in a clinical setting.
Gil-Garcia, A. I., Lopez-Lopez, A., Rubio, J. M., Montoya, J. J., Ouahid, Y., Madejon, A., Castan, P.
10.1101/2022.01.18.22269401 — Posted: 2022-01-26
Seroepidemiological and genomic investigation of COVID-19 spread in North East region of India
Wahengbam, R., Bharali, P., Manna, P., Phukan, T., Singh, M. G., Gogoi, G., Tapadar, Y. B., Singh, A. K., Konwar, R., Chikkaputtaiah, C., Velmurugan, N., Nagamani, S., Mahanta, H. J., Sarma, H., Sahu, R. K., Dutta, P., Wann, S. B., Kalita, J., Sastry, G. N.
10.1101/2022.01.25.22269702 — Posted: 2022-01-26
Comprehensive fitness landscape of SARS-CoV-2 Mpro reveals insights into viral resistance mechanisms
Flynn, J. M., Samant, N., Schneider-Nachum, G., Barkan, D. T., Yilmaz, N. K., Schiffer, C. A., Moquin, S. A., Dovala, D., Bolon, D. N. A.
10.1101/2022.01.26.477860 — Posted: 2022-01-26
SARS-CoV-2 Omicron Variant AI-based Primers
Perez-Romero, C. A., Tonda, A., Mendoza-Maldonado, L., MacSharry, J., Szafran, J., Claassen, E., Garssen, J., Kraneveld, A. D., Lopez-Rincon, A.
10.1101/2022.01.21.475953 — Posted: 2022-01-26

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).